



Yaniv Sneor <mabafunds@gmail.com>

FW: Evrys Bio Q2 Financials

2 messages

Lillian Chiang <lillian@evrysbio.com>
To: Yaniv Sneor <yaniv@bioangels.net>

Tue, Sep 1, 2020 at 6:37 PM

Yaniv – Find attached the redacted financials for sharing with your investors. Lillian

From: Lillian Chiang <lillian@evrysbio.com>
Date: Tuesday, September 1, 2020 at 6:36 PM
To: Lillian Chiang <lillian@evrysbio.com>
Cc: Karen Monzon <karen@evrysbio.com>, Brian Pusch <bpusch@puschgal.com>
Subject: Evrys Bio Q2 Financials

Dear Evrys Bio Investor,

Just a quick email to provide you the Q2 Financials (attached).

Lillian

From: Lillian Chiang <lillian@evrysbio.com>
Date: Saturday, June 27, 2020 at 9:47 AM
To: Lillian Chiang <lillian@evrysbio.com>
Cc: Karen Monzon <karen@evrysbio.com>, Brian Pusch <bpusch@puschgal.com>
Subject: Evrys Bio 2019 Report and 2020 Update

Dear Evrys Bio Investor,

I hope that today, June 26, 2020 finds you and your families well. We certainly are living in a different world from just a few months ago. I apologize for the protracted delay in getting Evrys Bio's 2019 Yearly Report to you. 2019 was, in fact, a great year for Evrys Bio. Evrys Management had essentially just completed its in depth 2020 strategic planning for the year to continue the momentum of 2019, when the COVID-19 outbreak began to seriously impact everyone. As has happened for every business, small or large, across the globe, Evrys Bio has been riding this rollercoaster of crisis, and in the case of biopharma – for opportunity as well. I am happy to report that for Evrys, the ups are outweighing the downs. Evrys is staying true to its vision to ultimately address every viral infection while responding to the more immediate global need to address coronavirus infection.

To give our investors a better picture of what has been happening here at Evrys, I am stepping out of my typical format for quarterly updates. You will find attached the complete 2019 Yearly Report. Also, you will find attached Evrys' unaudited quarterly financials for the period ending March 31, 2020. Find below, a timeline as to the goings-on here at Evrys since the beginning of the year – we have been busy. Overall, since the SARS-CoV-2 outbreak, Evrys continues on target to complete our pre-IND meeting by the end of this year with the FDA for our first product in transplant infections. Multiple non-dilutive funding opportunities have become available for COVID-19 research. Evrys has applied for several in an effort to bring in more government sponsorship of our pan-respiratory infections antiviral. As we enter into development for transplant infections, in-house efforts are shifting from cytomegalovirus to respiratory viruses (including coronaviruses) and HBV assays to select our second and third product lines. On the business development front, two significant events, John Martin, former Chairman of Gilead has joined as an advisor to Evrys, and Investor Advisor, Dana Fowlkes, has come on board as full-time CBO. Since the global outbreak, “flatten the curve” has become part of the lay lexicon – the tipping point has certainly arrived for a therapeutic approach by host-targeted antivirals to solve as opposed to react to the health and economic burden of viral infection.

Here's a summary of 2020:

Jan. 30 – Evrys Whitepaper, “Targeting Host Intrinsic Immunity to Treat Broad Spectrum Viral Infections”, given green light for MCDC full contract bid submission

Feb. 18 – First 2020 Board meeting: Approval of 2020 Budget and Goals

Mar. 1 – Evrys Publication: Acosta et al., Advances in the Development of Therapeutics for Cytomegalovirus Infections, *Journal of Infectious Disease*

Mar. 4 – Clinical Advisory Board meeting: Successful vetting of Evrys strategic development path for first product

Mar. 6 – MCDC full contract bid submission completed

Mar. 11 – Evrys Tax returns filed

Mar. 17 – State of Pennsylvania shut-down for COVID-19: Evrys Bio falls into “essential business” category. Initially we operated virtually for two weeks while we assessed risks and developed operations practices to minimize risk to laboratory personnel, who now work in shifts on site to minimize exposure and maximize social distancing

Apr. 6 – Evrys applies for CARES Act Paycheck Protection Program loan

Apr. 9 – NIH full contract bid submission completed, “A single-dose antiviral with effectiveness against myxo-, pneumo-, adeno-, corona- and herpes viruses to treat influenza-like illness and severe acute respiratory infection”

Apr. 23 – John Martin, former Chairman of Gilead, joins Evrys' Business Advisory Board

May 1 – NIH STTR Phase I (Epstein Barr virus collaboration with Duke University) and SBIR FastTrack (HBV) submissions completed

May 1 – NIH Emergency Award for COVID-19 research submission completed with Evrys coronavirus effectiveness data (see below)

May 6 – Scientific Advisory Board (SAB) meeting: Professor Nieng Yan of Princeton University joins Evrys SAB for update on Evrys sirtuin modulators

May 8 – CARES Act Paycheck Protection Program loan of \$125,000 closed

May 19 – Second 2020 Board meeting: Approval to hire Dr. Dana Fowlkes, Evrys Investor Advisor, as full-time Chief Business Officer, officially launching Evrys's full press mission in the next year to leverage COVID-19

infectious disease awareness to complete pharma partnering and/or equity financing

June 3 – Animal protocol submission for ferret study with St. Jude’s collaborators for influenza challenge study

June 5 – Evrys CEO presents at BIO NJ Rapid Fire COVID-19 Research Showcase

June 12 – DoD Congressionally Directed Medical Research Program (COVID-19) submission completed

June 22 – Completion of annual indirect cost negotiation with the Division of Financial Advisory Services of the NIH

I hope you find this information useful and thank you for your continuing support!

Lillian Chiang, PhD

President & CEO

Figure shows reduction of beta coronavirus OC43 RNA and protein with treatment by Evrys LEAD. Experiments are in progress to test beta coronavirus SARS-CoV-2.




Table shows broad-spectrum activity of Evrys LEAD with red emphasizing diverse respiratory viruses.

Virus	Virus family	FLS-359 EC ₅₀	Standard of Care Comparator EC ₅₀	Standard of Care or Comparator (C)	Assay performed by
JCV	polyomavirus	[0.05]	3.8	ribavirin (C)	NIAID
Zika	flavivirus	0.39	3.9	amodiaquine (C)	USAMRIID
HCoV-OC43	beta coronavirus	0.54	1.6	hydroxychloroquine (C)	Evrys Bio
CMV	herpesvirus	0.58	1.4	ganciclovir	Evrys Bio
BKV	polyomavirus	[0.85]	4.4	ribavirin (C)	NIAID
Influenza A	orthomyxovirus	EC ₉₀ = 1.2	EC ₉₀ = 0.03	oseltamivir	NIAID
Influenza B	orthomyxovirus	1.2	> 25	oseltamivir	Evrys Bio
Marburg	filovirus	1.5	2.4	USAMRIID reference (C)	USAMRIID
HCoV-229E	alpha coronavirus	1.6	0.04	remdesivir (C)	ImQuest
Ad5	adenovirus	1.6	3.1	cidofovir (C)	Evrys Bio
Influenza A ^R	orthomyxovirus	2.5	9	oseltamivir	Evrys Bio
Junin	arenavirus	3.2	0.17	USAMRIID reference (C)	USAMRIID
HBV	hepadnavirus	5.2	0.03	tenofovir	ImQuest
RSV	orthopneumovirus	6.7	16.1	ribavirin	Retrovirox



3805 Old Easton Road

Doylestown, PA 18902


Phone: 1-267-370-5436

Email: lillian@evrysbio.com

This email contains confidential information that belongs to Evrys Bio, LLC, and its reproduction and use is governed by Non-Disclosure Agreements or other contract(s) with confidentiality provisions signed between you and Evrys Bio.

If you received this information in error, please contact the sender and delete the material.

2 attachments

 **Statement of Income Q2-2020.pdf**
40K

 **Stmnt of Fin Pos Q2-2020.pdf**
52K

Yaniv Sneor <yaniv@bioangels.net>
To: Lillian Chiang <lillian@evrysbio.com>

Mon, Sep 14, 2020 at 1:17 PM

Lillian,

Received, thank you. I just realized that I had not yet confirmed.

Regards,

Yaniv

Yaniv Sneor
Co-Founder
Mid Atlantic Bio Angels (MABA)
www.bioangels.net
yaniv@bioangels.net
908-380-3932

[Quoted text hidden]

Evrys Bio, LLC

Confidential Unaudited Financial Statements STATEMENT OF FINANCIAL POSITION

	<u>June 30, 2020</u>	<u>December 31, 2019</u>
Assets		
Cash	\$ 539,196	\$ 992,037
Accounts Receivable	\$ -	\$ 383,788
Prepaid services *	\$ 842,821	\$ 655,933
Total current assets	<u>\$ 1,382,017</u>	<u>\$ 2,031,758</u>
Property and equipment		
Total Assets	<u><u>\$ 1,382,017</u></u>	<u><u>\$ 2,031,758</u></u>
Liabilities and members' equity		
Current Liabilities		
Accounts Payable	\$ 70,533	\$ 172,938
Other Current Liabilities	\$ 69,285	\$ 195,049
Total Current Liabilities	<u>\$ 139,818</u>	<u>\$ 367,986</u>
Long Term Liabilities		
PPP Loan	\$ 125,000	\$ -
Total Liabilities	<u>\$ 264,818</u>	<u>\$ 367,986</u>
Members' Equity		
Members' Equity	\$ 2,263,772	\$ 2,858,901
Net Income	\$ (1,146,573)	\$ (1,195,129)
Total Member's equity (deficit)	<u>\$ 1,117,199</u>	<u>\$ 1,663,772</u>
Total Liabilities and members' equity (deficit)	<u><u>\$ 1,382,017</u></u>	<u><u>\$ 2,031,758</u></u>

* *Prepaid services reference services in exchange for equity investment in Evrys Bio.
This will be drawn down as the services are completed.*

Evrys Bio LLC
Unaudited Financial Statements
STATEMENT OF INCOME

	For the six months ended June 30,	
	<u>2020</u>	<u>2019</u>
Revenues		
Revenue from government grants	\$ 374,522	\$ 274,094
Research contracts and tax credits	\$ 528	\$ 71,241
Total Revenue	<u>\$ 375,051</u>	<u>\$ 345,335</u>
Operating Expenses		
Research and Development	\$ 1,038,107	\$ 778,972
General and Administrative	\$ 483,516	\$ 449,531
Total Operating Expenses	<u>\$ 1,521,623</u>	<u>\$ 1,228,503</u>
Net Income (Loss)	<u><u>\$ (1,146,573)</u></u>	<u><u>\$ (883,168)</u></u>